We previously showed that congenic bone marrow transplantation (BMTx) post myeloablation augmented tissue allograft survival in association with increased regulatory T (Treg) cells of both host and bone marrow donor origin. Regulatory B (Breg) cells can also modulate T-cell immunity and B cells may be implicated in the development of Treg cells. Accordingly, we explored the effect of B-cell depletion in vivo on augmented graft survival post BMTx. C57BL/6 mice received BALB/c skin allografts followed 7 days later by myeloablation using cyclophosphamide and busulphan. Mice then received T-cell-depleted bone marrow from CD45.1 congenic donors, and ongoing immunosuppression with rapamycin (to day 28 after BMTx). Control mice received cyclophosphamide and busulphan followed by rapamycin, but not congenic bone marrow. At different times post BMTx, mice received B-cell-depleting antibody treatment, and the effect on both skin graft survival, and induction of Treg cells was assessed. BMTx resulted in significantly prolonged skin graft survival versus control mice, in association with attenuated donor-specific alloreactivity relative to controls, increased splenic Treg cells and significantly diminished anti-donor IgG. In mice receiving infusion of B-depleting antibodies for 12 days from day 15 post BMTx, both graft survival and Treg cell activity were diminished, particularly for functional Treg cells of donor origin. Adoptive transfer of Breg cells from mice harvested at 15 days post BMTx prolonged survival in naive transplanted mice and increased Treg cell levels. Thus, autologous BMTx augmentation of graft survival is dependent in part upon a population of Breg cells that can modulate the function of donor-derived Treg cells.
Introduction
Although transplantation has become the preferred treatment for patients with end-stage organ failure, immune rejection, immunosuppressive drug-related toxicity, opportunistic infection and lympho-proliferative disorders are currently the major limitations to this treatment. 1 We previously showed that in either na€ ıve animals or in animals immune to graft tissue, transplanted with skin allografts, myeloablation followed by congenic bone marrow rescue (BMTx), improved allograft survival with nearly 40% of recipients retaining their grafts long-term, in the absence of immunosuppression. 2, 3 Long-term graft survival was associated with increased numbers of CD4 + Foxp3 + regulatory T (Treg) cells in recipients, which could actively suppress anti-graft reactivity. A similar approach has been used clinically in the treatment of refractory autoimmune disease. 4 B lymphocytes with immunosuppressive functions, socalled regulatory B (Breg) cells, have also been described in organ transplantation as well as post autologous haematopoietic stem cell transplants (HSCT). 5, 6 Clinically, it has been reported that treatment with rituximab [anti-CD20 monoclonal antibody (mAb)] for induction therapy led to increased transplant rejection compared with patients receiving daclizumab (anti-CD25 mAb). 7 In an islet allograft mouse model, transforming growth factor-b (TGF-b) -producing Breg cells augmented graft survival by increasing the number of Treg cells. 8 In patients receiving autologous HSCT for systemic sclerosis, increased numbers of Breg cells (defined as CD19 + CD24 hi CD38 hi ) were reported at 6 and 12 months post transplant with no alteration in the levels of Foxp3 + CD25 hi CD4 + Treg cells. 9 Regulatory networks between B and T cells, 10 and a role for interleukin-10 (IL-10) -producing Breg cells, have been reported in a clinical graft-versus-host disease model following cord blood transplantation. 11 Although these results imply an important role for Breg cells in promoting and maintaining immune tolerance, our earlier studies documented that in our model all suppressive function was lost from splenocytes harvested from transplanted mice following depletion of Thy-1.2 + T cells, ostensibly eliminating a role for Breg cells in prolonging allograft survival. 2, 3 However, we acknowledged that we had not eliminated an important effect of Breg cells in vivo at earlier times during induction of the tolerant state, or indeed in the induction of Treg cells themselves. The fact that Treg cell functional activity was only demonstrable at~40 days post transplantation, but grafts were still not rejected at earlier times, 2, 3 might imply the existence of alternative regulatory cell populations at early times post transplantation.
The current studies were designed to explore directly any involvement of Breg cells in increased allograft survival following autologous marrow transplantation, using in vivo depletion with anti-CD19 antibody beginning at various times post marrow transplantation (days 5, 15 or 25). We show that graft survival and mixed lymphocyte co-culture (MLC) hyporesponsiveness were diminished in mice treated from day 15 post BMTx with two doses of anti-CD19 antibody. In anti-CD19 untreated mice, we observed B220 + (Breg) suppressive function at this time, and a preferential loss of CD4 + Treg cells of donor (but not host) origin in mice receiving autologous BMTx and anti-CD19 antibody beginning at day 15 post BMTx. Adoptive transfer of B220 + cells from BMTx mice harvested 15 days post marrow infusion to naive skin allograft recipients prolonged graft survival, in association with evidence for augmentation of Treg cells in such recipients.
Materials and methods

Mice
Stock wild-type male C3H/HeJ, BALB/c, C57BL/6.CD45.2 (BL/6) and BL/6.CD45.1 congenic mice were purchased from the Jackson Laboratories (Bar Harbour, ME) and housed as previously described. 2 All animals were handled according to the recommendations of the Canadian Council for Animal Care (CCAC) and all animal protocols (AUP. 1.19) were approved by the Animal Resource Center, University Health Network.
Media and cell lines
For in vitro assays, complete aMEM (aF10) supplemented with 10% fetal calf serum and 2-mercaptoethanol was used. P815 tumour cells and C3H spleen cell blasts (72 hr stimulation with 5 µg/ml Concanavalin A) used for cytotoxic T lymphocyte (CTL) targets, were cultured throughout in aF10.
Monoclonal antibodies
The following mAbs were used: from BD Pharmingen (San Diego, CA): Fluorescein isothiocyanate-conjugated anti-mouse CD4 (RM4-4); from Biolegend (San Diego, CA): allophycocyanin-conjugated anti-mouse CD25 (3C7), allophycocyanin-conjugated anti-mouse CD3e (145-2C11), CD45.1 (clone A20), CD45.2 (clone 104); from Cedarlane Laboratories (Hornby, ON), anti-Thy-1.2 (Clone 5a-8) and anti-B220 (RA3-6B2); and from Serotec (Mississauga, Canada), fluorescein isothiocyanate-conjugated anti-CD3 (clone MCA500F). Rat anti-mouse CD19 for in vivo use was obtained from Origene (supplied by Cedarlane Laboratories); rabbit anti-IL-10/-TGF-b for in vivo use was obtained from Abcam (Cambridge, UK).
Anti-thy1.2 and anti-CD45.1/.2 antibody treatment
Bone marrow was obtained by flushing femurs and red blood cell lysis was performed using Ammonium Chloride Potassium lysis buffer. Cells used to reconstitute BL/6 mice were treated at a concentration of 5 9 10 6 cells/ml with anti-Thy-1.2 antibody and rabbit complement. T-cell depletion (≥ 99%) was confirmed by FACS staining. 2 In certain experiments, cells harvested from transplanted mice were treated with anti-CD45.1/.2 antibody (BioLegend) and rabbit complement before use in assays, as described below.
Skin grafting
BALB/c skin grafts to BL/6 naive or immune mice (i.e. having previously rejected BALB/c grafts) were performed as described in previous manuscripts -immune mice were those which had previously received and rejected (≥ 21 days earlier) a skin graft from the same donor as used in subsequent graft studies. 2, 3 All experimental naive/pre-sensitized transplanted mice subsequently received rapamycin (Wyeth, St.Laurent, QC, Canada; 1 mg/kg at 36 hr intervals) post transplantation.
For mice undergoing BMTx, myeloablation and marrow transplants were performed as follows. 3 Before the BMTx, rapamycin was stopped and individual mice received busulphan (20 mg/kg/day 9 4 days) followed by cyclophosphamide (100 mg/kg/day 9 2 days) before resting for 2 days. 2 Subsequently, the recipients (CD45.2) were injected intravenously with 5 9 10 6 T-cell-depleted CD45.1 congenic marrow. Five days post BMTx, subgroups of mice were restarted on rapamycin until day 35 post skin grafting. In certain cases, groups of BMTx mice also received infusions of rat anti-mouse CD19 (anti-Bcell) antibody, or normal rat serum as control, beginning at day 5, 15 or 25 days post marrow infusion. Animals received two infusions (10 µg/mouse) 1 week apart. Splenocytes were stained with anti-B220 mAb to assess Bcell depletion. In other studies (see text) mice received three infusions of rabbit anti-mouse anti-IL-10 or anti-TGF-b antibodies (or normal rabbit serum as control) post BMTx. In this case, animals received 7Á5 µg/mouse/ injection at the times indicated.
Quantification of donor-specific IgG and mixed leucocyte culture cytotoxicity assays Donor-specific (anti-BALB/c) antibody levels were determined using a standard cross-match assay as before, assessed via flow cytometry and data reported as median fluorescence intensities. 12 The CTL killing assays were performed as previously described:
2,3 1Á0 9 10 6 responder splenocytes from graft recipients were stimulated with equal numbers of irradiated donor (BALB/c) or third-party (C3H) stimulators in the presence of IL-2 (BioLegend). Cells from replicate wells were pooled at 5 days and titrated at different effector : target ratios for killing of 1 
Statistics
Most studies compared groups using analysis of variance followed by paired t-tests. For skin graft survival, groups were compared using non-parametric tests (Mann-Whitney U-test). All data are expressed as mean AE SD unless stated otherwise.
Results
Increased graft survival in naive and immune mice after autologous bone marrow transplantation occurs in association with increased host and donor-derived Treg cells
In our previous studies, skin allograft survival was markedly improved in both naive and immune mice after myeloablation using a short course of busulphan/cyclophosphamide, followed by autologous marrow transplantation and ongoing rapamycin treatment, 2, 3 with no such prolongation seen using rapamycin with busulphan/ cyclophosphamide in the absence of marrow transplantation. Data in Fig. 1 re-confirm these findings in a study using 15 CD45.2 BL/6 mice/group (naive or immune to BALB/c skin grafts), which subsequently received BALB/c Days post skin transplantation Per cent surviving allografts Figure 1 . Skin allograft survival following autologous bone marrow transplantation in naive and immune (i.e. previously grafted) mice -see text for further details. Fifteen animals/group of naive (▲) or immune (○) CD45.2 BL/6 mice (the latter having rejected a first BALB/c graft 21 days earlier) received BALB/c skin grafts and a sequence of rapamycin treatment, followed by busulphan/cyclophosphamide for 6 days, and a further 21 days of rapamycin treatment beginning 5 days later. Two additional groups of naive (▼) or immune (■) mice also received autologous T-cell-depleted CD45.1 BL/6 bone marrow cells (5 9 10 6 per recipient) 2 days after completion of the course of busulphan/cyclophosphamide, and began 21 days of rapamycin 3 days later. Data show graft survival for all four groups. *P < 0Á05 (Mann-Whitney U-test) for equivalent recipients without bone marrow. Fig. S1 ).
When splenocytes from grafted mice were tested individually in MLC for induction of donor-specific (versus third-party) CTL or proliferative MLR responses, a significant attenuation of donor-specific cytotoxicity (Fig. 2a) and proliferation (Fig. 2b) was observed in both naive and immune mice with accepted grafts compared with graft-rejecting animals (grouped data shown in Fig. 2a,b) . All groups showed similar CTL and MLR responses to third-party (C3H) stimulation (Fig. 2a,b) . 3 We also compared the titres of anti-donor IgG in five groups of mice. The groups are as follows, naive non-transplanted controls, and naive or immune mice treated with rapamycin and busulphan/cyclophosphamide (myeloablation), with or without subsequent bone marrow transplant. Serum was obtained at 60 days post skin transplant for all grafted mice. As shown in Fig. 2(c intensities) were significantly (P < 0Á0001) diminished in both naive and immune mice compared with similar groups of mice not receiving marrow.
3 Data in Fig. 2(d,e) show results for studies investigating evidence for functional Treg cells of host or donor bone marrow origin, by assessing antigen-specific suppression of CTL induction and MLR proliferative responses, respectively, in fresh naive BL/6 splenocytes using CD4 + -enriched cells harvested from transplanted mice.
2 Splenocytes were obtained from individual animals with longterm graft survival from both naive and immune transplant groups (n = 5/group) at 60 days post skin grafting. MLC were initiated using 3 9 10 6 responder cells pooled from four naive BL/6 mice, combined with either 1 9 10 6 whole spleens, or CD4 + -enriched cells for each graft recipient. For each whole spleen suspension or CD4 + -enriched fraction, cells were treated in vitro before culture with rabbit complement alone, or complement with anti-CD45.1 or anti-CD45.2 mAb (to deplete cells of donor or host origin, respectively). The MLC were stimulated with irradiated BALB/c or C3H cells (third-party) and assayed at 5 days for CTL specific for the stimulating antigen (Fig. 2d ), or at 72 hr for attenuation of proliferation (Fig. 2e) . Data in the Supplementary material (Fig. S2) show similar results for whole spleen cells. Both whole spleen cells and CD4 + -enriched splenocytes from mice with surviving grafts (naive and immune) resulted in antigen-specific suppression of both CTL induction and MLR proliferation from naive responder spleen cells. Treatment of splenocytes from grafted mice with either anti-CD45.2 or anti-CD45.1 before use in suppression assays led to attenuation of the suppression compared with that seen using cells treated with complement alone, implying the existence of regulatory populations that are derived from both host and donor marrow. Combination treatment with both anti-CD45.1 and anti-CD45.2 antibody with complement completely abolished all suppression seen, as indeed did treatment with anti-Thy1.2 and rabbit complement (see legend to Fig. 2d) . 3 We concluded that non-T cells were not likely to be responsible for the regulatory activity measured in splenocytes from grafted mice at 60 days post transplantation (the time of killing).
Effect of B-cell depletion in vivo beginning at 5, 15 and 25 days post BMTx on graft survival Breg cells can contribute to the induction of Treg cells and attenuation of immune responses including those contributing to graft rejection. 5, 6, [8] [9] [10] [11] 13 Based on the loss of all suppression seen in vitro following treatment of splenocytes from grafted mice with either anti-Thy1.2, or combined anti-CD45.1 and anti-CD45.2, we concluded that the regulation seen at 60 days post grafting was attributable to Treg cells and not to other populations (including Breg cells). However, a potential role for Breg cells in the induction of Treg cells at early times post BMTx had not been assessed. To test directly the importance of B cells to regulation of graft rejection following autologous BMTx, we performed the following study. Thirty-two naive CD45.2 BL/6 mice received BALB/c skin grafts, myeloablation and CD45.1 T-cell-depleted BMTx as before. A control group of five mice received no BMTx -the doses of chemotherapeutic drugs used were not lethally myeloablative and mice did not require bone marrow rescue for long-term survival. All mice received rapamycin beginning 11 days post skin grafts (3 days post BMTx). At 5, 15 and 25 days post BMTx, eight mice/ group received two doses (10 µg/mouse) of rat antimouse CD19, 1 week apart whereas control animals received normal rat serum only. The non-BMTx control received no such treatment. Graft survival was followed daily for all animals ( Fig. 3) , with the study halted at 60 days post transplantation.
Infusion of anti-CD19 antibody beginning at day 5 or day 25 post BMTx produced little to no attenuation of prolonged graft survival compared with mice receiving BMTx and normal rat serum [see Fig. 3 (○,▼,♦)]. Animals treated with anti-CD19 antibody from day 15 post BMTx, although having augmented graft survival relative to non-BMTx mice (compare ▲, ■), showed attenuated graft survival compared with all other BMTX groups (■ versus ○,▼,♦). B-cell depletion was assessed via FACS using the marker B220 (see legend to Fig. 3 ). Depletion was observed to be significant at the time of killing (day 60 post grafting) in all mice, which had received anti-CD19 treatment, with the most marked depletion seen in mice beginning 25 days post BMTx (i.e. given the last infusion of anti-CD19 only approximately 18 days before killing).
Effect of B-cell depletion with anti-CD19 on Treg and Breg cells in grafted mice receiving BMTx With the exception of mice from groups that received no BMTx or BMTx with anti-CD19 from day 15, cells were pooled within groups only for mice with surviving grafts. For mice given BMTx and anti-CD19 from day 15, cells were pooled for four donors with longest surviving grafts (> 32 days), although all grafts in this group were rejected by day 60. Figure 4 (a,b) shows that all mice receiving BMTx contained antigen-specific regulatory cells in splenocytes harvested at 60 days post grafting [see anti-donor (BALB/c) responses noted by * or *** in Fig. 4a,b ]. There were no statistically significant differences between groups in third-party (anti-C3H) antigen responses, which are not shown for sake of clarity. Regulation was attenuated in mice receiving anti-CD19 treatment from day 15 post BMTx (compare *** and * in Fig. 4a,b) , consistent with the graft survival data in Fig. 3 . Depletion of regulatory splenocytes with anti-Thy1.2 in all cases essentially abolished regulation as determined by absence of inhibition of anti-BALB/c CTL induction or of inhibition of proliferation (see **** in Fig. 4a,b) . However, addition of enriched B220 + cells did indicate evidence for non-Treg (presumably Breg) cell activity in splenocytes harvested from all mice except those treated from day 25 post BMTx (see ** in Fig. 4a,b , showing a decreased response compared with no BMTx control after addition of B220 + cells). Figure 5(a,b) examines the role of donor versus host CD4 + Treg cells in suppression of donor responsiveness in vitro using splenocytes of mice shown in Fig. 3 . In all groups receiving BMTx, there was evidence for both CD45.1 + (donor) and CD45.2 + (host) CD4 + Treg cells as defined by attenuated suppression of CTL activity and MLR proliferation following treatment with anti-CD45.1 or anti-CD45.2 (see ** and *** in Fig. 5a,b) . There was evidence of a greater sensitivity to CD45.2 depletion in groups of mice treated with anti-CD19 from day 5 or day 15 post BMTx (indeed in the latter case, CD45.1 + cells (see **** in Fig. 5a ,b) surviving following CD45.2 depletion failed to suppress anti-donor (BALB/c) alloreactivity). We conclude that attenuation of Treg cell induction occurred followed B-cell depletion commencing at day 15 post BMTx, with the greatest effect being a perturbation of development of Treg cell of donor, not host, origin.
Further evidence for a role for non-T (B cells) in induction of Treg cells post BMTx
As a final assessment of the potential for non-T (enriched B cells) to induce Treg cells following autologous BMTx, we performed the following study. Groups of five mice each received myeloablation and T-cell-depleted bone marrow, or myeloablation alone as before (see Materials and methods). Fifteen days post BMTx mice in both groups were killed, and T cells were depleted with antiThy1.2 and complement (% surviving CD3 + cells < 3% in both cases). B220
+ -enriched cells (by MACS) were isolated from one half (~1Á50 9 10 8 cells) of each pool, with recovery from the column~1Á0 9 10 7 cells in each case. Cells from all four groups were then infused into groups of five naive BL/6 recipients receiving BALB/c skin grafts (3Á0 9 10 7 T-depleted cells or 2Á0 9 10 6 B220 + enriched cells per recipient). Graft survival was monitored for 21 days (Fig. 6 ) after which all mice were killed. Splenocytes from individual mice were harvested and assessed in MLRs only for [ 3 H]TdR incorporation at 72 hr after stimulation with irradiated BALB/c or C3H stimulator cells (Fig. 7a) . In addition, cells from each grafted mouse were added, before/after further T-cell depletion using anti-Thy1.2 and complement, to cultures of naive mice stimulated with BALB/c or C3H cells to measure evidence for inhibition of MLR responses (Fig. 7b) .
There are a number of key features in these data. First (Fig. 6 ), adoptive transfer of T-depleted cells, or All data shown are for graft survival of n = 8 mice/group. Four groups of mice received BMTx beginning 2 days after completion of myeloablation. Three of these groups subsequently received anti-CD19 antibody (10 lg/mouse; two doses, 1 week apart, beginning 5, 15 or 25 days post BMTx). A control group received normal rat serum (NRS). * indicates P < 0Á05 compared with all other groups (Mann-Whitney U-test). ** indicates P < 0Á05 compared with either (▲) or (○,▼,♦ 
B220
+ enriched cells, from mice 15 days post autologous BMTx to naive recipients leads to measureable prolongation of survival of skin grafts in those animals. Consistent with these data, splenocytes harvested from these adoptive transfer recipients showed antigen-specific attenuation of MLR proliferation in 72 hr cultures after stimulation with the original graft antigens (BALB/c) (Fig. 7a) . Most interestingly, although this attenuation of MLR proliferation resulted from adoptive transfer of T-depleted cells (or enriched B220 + cells), the cells apparently active in causing antigen-specific suppression were Treg cells. This is evident from the loss of suppression when splenocytes from these adoptive transfer recipients were used themselves in vitro, after T-cell depletion, to inhibit MLR responses of fresh naive cells (Fig. 5b) . We conclude that Breg cells from mice at day 15 post BMTx induced T reg cells on adoptive transfer.
Effect of anti-IL-10 or anti-TGF-b on development of Treg (Breg) cells post BMTx
Interleukin-10 and/or TFG-b are thought to be implicated in a role for Breg cells in transplant tolerance, and/or the development of Treg cells. 5 To investigate their role in the activity reported in grafted mice receiving autologous BMTx, we performed the following study. Naive BL/6 mice (n = 4/group) received BALB/c skin allografts followed by myeloablation and congenic BMTx as before, with a control group receiving no BMTx. Beginning 10 days post BMTx, subgroups of mice received three injections 5 days apart of either rabbit anti-mouse IL-10 or anti-mouse TFG-b antibody (7Á5 lg/mouse) -controls received normal rat serum. Mice were killed at 60 days post grafting, splenocytes were pooled within each group, and aliquots were treated either with anti-Thy1.2 and complement to deplete T cells, or enriched for B220 + cells. Then, 1 9 10 6 cells of all groups were added as putative regulatory cells to MLCs of fresh BL/6 splenocytes stimulated with irradiated BALB/c or C3H cells. CTL were assayed at day 5 and MLR proliferation at 72 hr, with data pooled from two such studies shown in Fig. 8(a,b) , respectively.
Treatment of BMTx mice with either anti-IL-10 or anti-TGF-b attenuated suppression mediated in vitro by cells harvested from those mice. However, there was no conclusive evidence that the loss of regulatory activity was more apparent in the T-cell compartment (see data comparing cells treated with anti-Thy1.2 versus untreated cells of the same type) or B-cell compartment (compare B220 + cells of all groups with those obtained from mice with no BMTx). responses in all groups and treatment conditions were equivalent with no statistically significant differences observed and so are not shown for clarity. *, ** P < 0Á05 compared with equivalent no BMTx control; ***P < 0Á05 compared with BMTx groups receiving either BMTx +NRS (no anti-CD19) or BMTx+anti-CD19 from day 5; ****P < 0Á05 compared with untreated cells from mice of the same treatment group. 
Discussion
A high success rate of skin graft acceptance in rodents, with withdrawal of all immunosuppression in recipients, was achieved in mice receiving autologous BMTx in our studies, 2, 3 an effect mirrored by recent reports using autologous HSCT in humans suffering from intractable autoimmune disorders. 4, 9 Graft survival was associated with existence of Treg cells of both recipient and donor bone marrow origin. 2, 3 A profound decrease in antidonor antibodies was reported, even in a scenario in which immune mice were used as transplant recipients, 3 implying that disruption of B-cell development and plasma cell survival was a feature of the protocol used (Fig. 1c) . Other mechanisms, not investigated but associated with the treatment protocol (busulphan/ cyclosphosphamide/ rapamycin), are probably also contributory factors in the marked decline in levels of pre-existing antibodies in such immune mice, although clearly BMTx is an important factor (Fig. 2c) . Thus, despite the high serum levels of anti-donor immunoglobulin in both naive and immune mice receiving cyclophosphamide/busulphan and rapamycin without BMTx, > 100-fold lower levels were observed in similar recipients post BMTx. 3 We previously ascribed this to the existence of a population post BMTx capable either of suppressing immunoglobulin production by surviving host cells (Breg cells), or attenuating (and/or competing for) their survival per se, and the data shown again support this hypothesis. Nevertheless, cells from grafted animals lost all ability to attenuate donor reactivity in naive cells in vitro following T-cell depletion, implying that non-T cells were not a key feature. The studies reported above aimed to assess whether non-T-cell populations might be implicated, at earlier times, in the development of Treg cell.
Regulatory B cells, a heterogeneous group of B lymphocytes with immunosuppressive functions, 5, 6 have attracted a great deal of interest in transplant models. 8, 10, 11, 13 TGFb-producing Breg cells promote graft survival by increasing the number of Treg cells, 8 but Breg cells can also mediate tolerance in other ways. In a cardiac allograft model, long-term graft survival was achieved by overexpression of the immunosuppressive molecule FGL2.
14 Tolerance in this model could be adoptively transferred through splenic B lymphocytes alone and was associated with strikingly diminished donor-reactive antibodies.
14 As mentioned previously, in patients receiving autologous HSCT for systemic sclerosis, increased Breg cells were seen at 6 and 12 months post transplant with no differences observed in levels of Treg cell. 9 All transplanted mice in our studies receive rapamycin post transplantation of both skin and marrow, and this drug can regulate intra-graft infiltration of Breg cells in vivo in association with augmented graft survival. 13, 15 To date, Breg cell subsets with various phenotypes (such as B10 cells and marginal zone B cells) have been defined but there is no consensus as to which surface markers are definitive. 5 Due to the heterogeneity in phenotypes among putative Breg cell populations, we did not assess surface marker profiles in our study but instead sought to validate functionally the existence of a suppressor B-cell population in vivo. In the studies above we infused B-cell-depleting antibodies into mice at different times post BMTx, and studied the subsequent effects on both graft survival and development of functionally active Treg cells, or B220 We speculate that differentiation of host-derived Treg cells precedes BMTx, and so is relatively refractory to Bcell depletion, whereas donor-derived Treg cells are in part at least dependent upon donor-marrow-derived Bcell development for their own induction. As further evidence for a role for donor-derived (from BMTx) Breg cells in induction of Treg cells, data in Fig. 6 show that adoptive transfer of T-cell-depleted (or B220 + ) cells from BMTx mice, but not non-BMTx mice, at 15 days after marrow infusion could induce augmented graft survival in naive mice. This occurred in association with antigenspecific decreased MLR proliferation in these recipients (Fig. 7a) , and an ability of Treg cells from those adoptive transfer recipients to suppress MLR responses in vitro from naive responder cells (Fig. 7b) . A recent report suggesting that in B-cell-deficient animals, Treg cells were both phenotypically and functionally different from those seen in wild-type animals adds a further layer of complexity to the interpretation of these data. 16 Interleukin-10 and other cytokines expressed by Breg cells are implicated in their function.
17,18 Figure 8 shows that both anti-IL-10 and anti-TGF-b caused a marked attenuation of development of suppressive activity in our model (compare ** and * in Fig. 8a,b) , although no definitive evidence was observed that could attribute the effect as mediated primarily through altered Treg versus Breg activity. Despite the absence of lineage-specific markers (akin to Foxp3 for Treg cells), a number of putative Breg subsets have been described in the literature. 5, 19 Most of these subsets display immature phenotypes suggestive of cells undergoing development. 5 Re-setting the immune system through autologous HSCT could potentially engage any of these Breg subpopulations, and which one is more critical for Treg cell induction remains open for investigation. Note too that following infusion of anti-CD19 into mice, massive apoptosis would be expected, and this has itself been associated with immunoregulatory consequences, and enhanced release of regulatory cytokines including TGF-b and IL-10. 20 However, the ability of infusion of enriched B220 + cells to induce immunoregulation in vivo (see Fig. 6 ) suggests that the ability of anti-CD19 treatment to attenuate immunoregulation represents a mechanism marked by deletion of the responsible Breg cells, and not a reflection of engagement of an alternative pathway involving apoptotic cells.
Regulatory T cells induced following BMTx can be expanded, with further improved graft survival, by mAbs to TNFRSF25. 2, 3, 21 Whether this remains true in situations where mice receive further manipulations (B-cell depletion; anti-cytokine sera) which might alter both Breg, and subsequent Treg, phenotype and/or function, also remains 
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